The low-phospholipid-associated cholelithiasis LPAC syndrome is a form of symptomatic cholelithiasis occurring in young adults, characterized by recurrence of symptoms after cholecystectomy and presence of hepatolithiasis. The case refers to a healthy year-old Caucasian male who presented with abdominal pain and jaundice. His blood tests showed conjugated hyperbilirubinemia and elevated liver enzymes total bilirubin 6. After an extensive workup including liver biopsy, the identification of two foci of hepatolithiasis on reevaluation abdominal ultrasound raised the hypothesis of LPAC syndrome and the patient was started on ursodeoxycholic acid, with remarkable improvement. Genetic testing identified the mutation c. In conclusion, we describe the unique case of an adult male with choledocholithiasis, hepatolithiasis, and persistent conjugated hyperbilirubinemia after retrieval of stones, fulfilling the criteria for LPAC syndrome and with possible superimposed drug-induced liver injury, in whom ABCB4 and ABCB11 mutations were found, both of which had not been previously described in association with LPAC.
|Published (Last):||6 October 2017|
|PDF File Size:||18.7 Mb|
|ePub File Size:||1.94 Mb|
|Price:||Free* [*Free Regsitration Required]|
No se han descrito efectos adversos.. Ursodeoxycholic acid, used in the treatment of in-trahepatic cholestasis present in the chronic liver diseases such as, primary biliary cirrhosis, primary sclerosing cholangitis or chronic hepatitis, is contra-indicated in pregnant women as there are no studies of its use in pregnancy..
In both cases, pruritus regressed completely after 3 days of treatment and plasma levels of biliary acid and transaminases began to decrease. Both infants, born between the 37th and 38th weeks, were normal.. Of these 18 cases were in 2 randomised studies.
In 49 cases pruritus had generally disappeared 3 days after the start of treatment and plasma levels of biliary acids and transami-nases decreased in one week.
Only two patients experienced persistent pruritus, although the biological criteria of cholestasis had decreased. No foetal teratogenicity or toxicity was observed.. Ursodeoxycholic acid seems to be an efficient treatment of gravid cholestasis. Long term observation of children exposed to this treatment in utero are required to confirm its apparent foetal safety.. ISSN: X. Descargar PDF. Moro , A. Teijelo , F.
Benavente , F. Corredera , A. Hospital Virgen de la Vega. No se han descrito efectos adversos. Ursodeoxycholic acid, used in the treatment of in-trahepatic cholestasis present in the chronic liver diseases such as, primary biliary cirrhosis, primary sclerosing cholangitis or chronic hepatitis, is contra-indicated in pregnant women as there are no studies of its use in pregnancy. Both infants, born between the 37th and 38th weeks, were normal. No foetal teratogenicity or toxicity was observed.
Long term observation of children exposed to this treatment in utero are required to confirm its apparent foetal safety.
Acta Med Scand, , pp. Fallon, C. Cunningham, P. MacDonald, N. Gant, K. Williams obstetricia, 20, pp. Principios de medicina interna I, 14, pp. Metabolismo de la bilirrubina e hiperbilirru-binemia. Principios de medicina interna II, 14, pp. Jaundice during pregnancy: A clinical study. Liver disease in pregnancy, with particular emphasis on the colestatic syndromes. Aust Ann Med, 17 , pp. Reyes, N. Ribalta, H. Aburto, C. Matus, G. Sch-ramm, et al.
Prevalence of intrahepatic cholestasis of pregnancy in Chile. Ann Intern Med, 88 , pp. The enigma of intrahepatic cholestasis of pregnancy: lessons from Chile. Hepathology, 2 , pp. The spectrum of liver and gastrointestinal disease seen in cholestasis in pregnancy. Gastroenterol Clin North Am, 21 , pp. Jones, J. Weaver, E. Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid. Gut, 37 , pp. Reyes, M.
Iglesias, M. Arrese, J. Po-niachik, et al. S-adenosyl-L-methionine in the traitment of patients of intrahepatic cholestasis of pregnancy: a randomi-sed double-bling, placebo-controlled study with negative results. Hepatology, 13 , pp. J Gynecol Obstet Biol Reprod, 22 , pp. Rennevik, S. Jeppsson, S.
Effect of oral contraceptives on the liver in women with recurrent cholestasis hepatosis during previous pregnancies. J Obstet Gynaecol Br Commonw, 79 , pp.
Calmelet, D. Coumaros, B. Viville, J. Raiga, J. Favreau, A. A propos de 3 observations. J Gynecol Obstet Biol Reprod, 27 , pp. Fisk, W. Bye, GNB. Maternal features of obstetric cholestasis: 20 years experience at King George V Hospital. Schorr-Leswick, E. Lebovics, B. Dworkin, W. Am J Gastroenterol, 86 , pp. Reyer, M. Arrese, D. Figueroa, B. Lorca, M. Andressen, et al. Intrahepatic cholestasis of pregnancy in twin pregnancies.
J Hepatol, 9 , pp. Furthoff, K. Jaundice in pregnancy. A follow-up study of the series of women originally reported by L. The pregnancies. Familial recurrent intrahepatic cholestasis of pregnancy: evidence for a dominant, possibly autosomal trait.
Hepatology, 2 , pp. Familiar recurrent intrahepatic cholestasis of pregnancy: concomitant occurrence of a shared HLA ha-plotype in effected members. Holzbach, D. Sivak, W. Familial recurrent in-trahepatic cholestasis of pregnancy: a genetic study providing evidence for transmission of a sex-limited, dominant trait. Gastroenterology, 85 , pp. Larrey, B. Rueff, G.
Feldmann, C. Degott, G. Dannan, J. Recurrent jaundice caused by recurrent hypere-mesis gravidarum. Gut, 25 , pp.
A Complex Case of Cholestasis in a Patient With ABCB4 and ABCB11 Mutations
Balistreri WF. Liver disease in infancy and childhood. Philadelphia: Lippincott-Raven, ; pp. Colestasis neonatal. Bol Med Hosp Infant Mex ; Karpen SJ. Update on the etiologies and management of neonatal cholestasis.
Print Download. Examples: Cancer AND drug name. Pneumonia AND sponsor name. How to search [pdf]. For these items you should use the filters and not add them to your search terms in the text field.